Description
In the Q2 FY2024 earnings for ResMed, the company registered strong execution across its entire business, reflecting in double-digit top and bottom-line growth. The results were primarily driven by double-digit global growth in both devices and its Software as a Service (SaaS) business. ResMed is addressing a significant problem considering there are over 2 billion people worldwide suffering from sleep apnea, chronic obstructive pulmonary disease, respiratory insufficiency resulting from neuromuscular disease, or insomnia. The company believes this constitutes a healthcare epidemic, and the firm is uniquely positioned to help solve this problem, making its offering potentially critical on a global scale.
Our Report Structure:
⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
⦁ Disclosures
Want unlimited access to our reports? Purchase our $99 annual subscription!
